Instem PLC
LSE:INS
Instem PLC
LSE:INS
Price:
830 GBX
Market Closed
Updated:
May 14, 2024
P/E
Price to Earnings
Price to Earnings
56.1
Current
56.1
Median
23.9
Industry
Lower
than median
Higher
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=56.1
Market Cap
/
190m
Net Income
3.4m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| UK |
|
Instem PLC
LSE:INS
|
190m GBP | 56.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
32.9B USD | 62.6 | |
| US |
|
Cerner Corp
NASDAQ:CERN
|
27.9B USD | 47.3 | |
| US |
|
Change Healthcare Inc
NASDAQ:CHNG
|
9B USD | -116.8 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
11.8B AUD | 169.6 | |
| JP |
|
M3 Inc
TSE:2413
|
1.1T JPY | 24.6 | |
| US |
|
Inspire Medical Systems Inc
NYSE:INSP
|
4.7B USD | -297.5 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.4B USD | 31.8 | |
| SE |
|
Sectra AB
STO:SECT B
|
46B SEK | 108.3 | |
| US |
|
Evolent Health Inc
NYSE:EVH
|
2.8B USD | -19.3 | |
| US |
|
Vocera Communications Inc
NYSE:VCRA
|
2.8B USD | -324 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
26.1
2-Years Forward
P/E
20.7
3-Years Forward
P/E
16.3
You don't have any saved screeners yet
